Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T101 Combined with Nucleoside Analogues in Chronic Hepatitis B
NCT04189276Phase 2Unknown
- Sponsor
- Tasly Group
- Start
- Dec 2019
- Primary completion
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of T101 in Chronic Hepatitis B (CHB), sponsored by Tasly Group. Status: unknown.
02
Drugs
T101
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04189276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04189276.